How Do You Lose Weight with Zepbound?

Last reviewed: June 18, 2026

Last updated: June 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Zepbound works by agonism at two receptors at once. The Zepbound prescribing information describes tirzepatide as a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist, and the label indicates it in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight plus at least one weight-related comorbid condition. The phrase "in combination with" is doing real work: in the registration trials the medication was never tested alone.

The Dual-Receptor Mechanism

Most incretin therapies for weight act at the GLP-1 receptor. Tirzepatide acts there and at the receptor for glucose-dependent insulinotropic polypeptide, the other major incretin hormone released from the gut after eating. That dual action is the structural difference between tirzepatide and semaglutide products and the reason their trial results are not interchangeable.

Downstream, incretin receptor agonism slows gastric emptying, enhances glucose-dependent insulin secretion, and acts on central pathways regulating appetite and satiety. The subjective experience most people report — feeling full sooner and thinking about food less — follows from those effects rather than from any direct action on fat tissue.

What the Trials Measured

The pivotal obesity trial, published as Tirzepatide Once Weekly for the Treatment of Obesity, ran 72 weeks in 2,539 adults and reported mean weight changes of −15.0, −19.5, and −20.9 percent across the three dosages studied versus −3.1 percent with placebo.

The later head-to-head trial, Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, randomized 751 adults with obesity and without type 2 diabetes to the maximum tolerated dose of each drug for 72 weeks. Least-squares mean weight change was −20.2 percent with tirzepatide versus −13.7 percent with semaglutide, and mean waist circumference change was −18.4 cm versus −13.0 cm.

The Dosing Framework That Produced Those Results

The labeled starting dosage for all indications is 2.5 mg injected subcutaneously once weekly for four weeks, and the label is explicit that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage. After four weeks the dosage increases to 5 mg weekly, with further increases permitted in 2.5 mg increments after at least four weeks on the current dose.

Recommended maintenance dosages for weight reduction and long-term maintenance are 5, 10, or 15 mg once weekly, with 15 mg the maximum recommended dosage. The label instructs prescribers to consider treatment response and tolerability when selecting a maintenance dosage and to consider a lower one if a patient does not tolerate it. That is a clinical judgment, not a self-selected target.

Tolerability Shapes Who Gets to the Results

In the pooled weight-reduction trials, gastrointestinal adverse reactions occurred in 56 percent of patients at each of the 5, 10, and 15 mg dosages versus 30 percent with placebo. Nausea was reported in 25, 29, and 28 percent versus 8 percent; diarrhea in 19, 21, and 23 percent versus 8 percent; constipation in 17, 14, and 11 percent versus 5 percent.

Across both trials, 4.8, 6.3, and 6.7 percent of patients at 5, 10, and 15 mg permanently discontinued because of adverse reactions versus 3.4 percent with placebo, and the label notes most who discontinued did so in the first few months for gastrointestinal reasons. Managing that window with your prescriber is what determines whether you reach a maintenance dosage at all.

The Diet and Activity Arm Was Not Optional

The indication reads "in combination with a reduced-calorie diet and increased physical activity," and the trials operationalized it. One trial in the programme included an intensive lifestyle intervention lead-in period, and 287 patients were treated for up to 72 weeks within it. Another was a randomized withdrawal design in which 783 patients were treated for up to 36 weeks and 335 of them for up to 88 weeks.

Reading the headline percentages as the effect of an injection alone misstates what was tested. The comparator arms were also dieting and increasing activity; the drug effect is the difference between arms, not the total change.

Body Composition and What Else Moves

Any large energy deficit reduces lean mass alongside fat. Adequate dietary protein and resistance training are the standard countermeasures in obesity medicine and apply here as they would to any weight-reduction programme.

Other endpoints move too. Waist circumference was a key secondary endpoint in the head-to-head trial. Zepbound also carries a second indication — moderate to severe obstructive sleep apnea in adults with obesity — which is itself a downstream benefit of weight reduction in a specific population. Tracking more than scale weight gives a truer picture of what treatment is doing.

What This Does Not Mean

The label states as a limitation of use that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Stacking is not a strategy.

And compounded tirzepatide is not an FDA-approved finished product. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing; they are prepared by a licensed pharmacy pursuant to a prescription for an individual patient. No compounded preparation is a generic version of Zepbound, because none exists.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How does Zepbound cause weight loss?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonist. Agonism at those receptors slows gastric emptying, enhances glucose-dependent insulin secretion, and acts on central pathways regulating appetite and satiety. The label indicates it in combination with a reduced-calorie diet and increased physical activity, and the trials tested it that way rather than as a standalone intervention.

How much weight was lost in the Zepbound trials?

The pivotal 72-week obesity trial in 2,539 adults reported mean weight changes of −15.0, −19.5, and −20.9 percent across the three dosages studied versus −3.1 percent with placebo. A 72-week head-to-head trial in 751 adults with obesity and without type 2 diabetes reported −20.2 percent with tirzepatide versus −13.7 percent with semaglutide, using maximum tolerated doses of each.

What are the most common side effects?

Gastrointestinal reactions dominate. In the pooled weight-reduction trials they occurred in 56 percent of patients at each of the 5, 10, and 15 mg dosages versus 30 percent with placebo. Nausea was reported in 25, 29, and 28 percent versus 8 percent on placebo; diarrhea in 19, 21, and 23 percent versus 8 percent; vomiting in 8, 11, and 13 percent versus 2 percent. Most discontinuations occurred early.

Do I still need to change my diet?

The indication itself specifies use in combination with a reduced-calorie diet and increased physical activity, and the registration trials tested that combination rather than the drug alone. The comparator arms were also dieting and increasing activity, so the headline percentages represent a combined intervention. Reading them as the effect of an injection by itself overstates what was studied.

Is Zepbound the same as Mounjaro?

They share the same active ingredient but are separate products with separate FDA applications and labeling. Zepbound is indicated for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is indicated only for improving glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Coverage often follows the indication rather than the ingredient.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.